New immune booster shows promise in early breast cancer trial
NCT ID NCT02950259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new immune-boosting treatment called IRX-2 in 16 people with early stage breast cancer. The goal was to see if giving IRX-2 before chemotherapy is safe and helps the immune system fight the tumor. The treatment was given before surgery, and researchers looked for any delays in surgery and changes in immune cells inside the tumor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch could spot nerve damage before it starts
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Six-Gene clue: could a simple test forecast lung spread in breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?